IOR - Institute of Oncology Research, Bellinzona, Switzerland.

Revlimid’s approval in this setting was based on the AUGMENT trial, which included patients with follicular lymphoma as well as another type of NHK known as marginal zone lymphoma. That showed a ...

The pairing of Revlimid (lenalidomide) and Rituxan (rituximab) – known as the R 2 regimen – has been cleared for patients with previously-treated follicular lymphoma (FL) and marginal zone ...

Among some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, treatment with the bispecific antibody odronextamab has been associated ...

Non-Hodgkin lymphoma is a cancer that affects lymphocytes, a type of white blood cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade ...

MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...

The Pakistani rupee posted marginal decline against the US dollar, depreciating 0.05% during trading in the inter-bank market on Monday. At close, the local currency settled at 280.87 against ...

CLN-B-NHL 的亚型多样，包括 5 例滤泡性淋巴瘤（Follicular lymphomas，FL）、1 例套细胞淋巴瘤（Mantle cell lymphoma，MCL）和 1 例结内边缘区淋巴瘤（Nodal marginal zone lymphoma，NMZL） 。在病理特征上，PTC 组织中 BCL-2 表达减弱，Cyclin D1 表达增强；淋巴瘤细胞则有各自独特的 ...

In a major milestone, four wind, solar and battery projects have been granted the right to connect to new power lines in the South West Renewable Energy Zone (REZ). These landmark projects will help ...

"This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” said Sarah ...